Web Results

www.pacermonitor.com/public/case/22927048/BROWN_v_ASTRAZENECA_PHARMACEUTICALS_LP_et_al

Nov 6, 2017 ... BROWN v. ASTRAZENECA PHARMACEUTICALS LP et al (2:17-cv-11209), New Jersey District Court, Filed: 11/06/2017 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.

www.pacermonitor.com/public/case/22954727/HAMPTON_v_ASTRAZENECA_PHARMACEUTICALS_LP_et_al

Nov 9, 2017 ... HAMPTON v. ASTRAZENECA PHARMACEUTICALS LP et al (2:17-cv-11480), New Jersey District Court, Filed: 11/09/2017 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.

www.patentdocs.org/new_biotech_cases

Sep 4, 2016 ... Gavel About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Horizon Therapeutics, Inc. v. Lupin Ltd. et al. 1:16-cv- 04438; ... Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; Zeneca Inc. ... Defendants: Lallemand Specialties, Inc.; Mascoma LLC.

www.patentdocs.org/2016/09/court-report.html

Sep 4, 2016 ... By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Horizon Therapeutics, Inc. v. Lupin Ltd. et al. 1:16-cv-04438; filed July 21, 2016 in the District Court of New Jersey • Plaintiff: Horizon Therapeutics, Inc. • Defendants: Lupin Ltd.; Lupin ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4023886

Apr 7, 2014 ... Because PML-RARα is a dominant-negative inhibitor of PML (Daniel et al, 1993), we asked whether PML-RARα activated HIF-1α through PML inhibition. ... Enrichment analysis revealed that genes belonging to this signature were significantly enriched in the genes upregulated in APL vs normal ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2645341

Aug 26, 2008 ... Successful treatments will require discovery of agents that select among multiple subtypes of nAChRs (Role, 1992; Gotti et al., 2007). To choose appropriate drugs and to avoid off-target effects, one must understand how each nAChR is distributed among cell types and contributes to neuronal function and ...

breast-cancer-research.biomedcentral.com/track/pdf/10.1186/bcr3618?site=breast-cancer-research.biomedcentral.com

Feb 17, 2014 ... Abstract. The mammalian target of rapamycin (mTOR) pathway is a central pathway that regulates mRNA translation, protein synthesis, glucose metabolism, lipid synthesis and autophagy, and is involved in malignant transformation. Several randomized trials have shown that the use of mTOR inhibitors ...

www.abcsg.org/wp/wp-content/uploads/2011/10/Clin-Cancer-Res-2008.pdf

5 years of tamoxifen (Nolvadex, AstraZeneca Pharmaceuticals) plus. 3 years of goserelin (Zoladex, AstraZeneca ... detected by means of the UltraVision LP detection system according to the manufacturer's recommendations (Lab Vision ..... Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1in ...

jpet.aspetjournals.org/content/jpet/315/1/222.full.pdf

metastasis during the course of their disease (Greenberg et al., 1999). Delivery of classic antifolate compounds such as metho- trexate to the brain has been a major challenge for the. This work was supported by National ... was kindly provided by AstraZeneca Pharmaceuticals LP (Wilming- ton, DE). Indomethacin was ...